Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab.

导出 OA

翻译打印收藏纠错

作者： Weifeng,Tang ^[1] ; Raj,Tummala ^[2] ; Joachim,Almquist ^[3] ; Michael,Hwang ^[4] ; Wendy I,White ^[5] ; David W,Boulton ^[5] ; Alexander,MacDonald ^[6]

作者单位： Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, USA. Weifeng.Tang@astrazeneca.com. ^[1] Clinical Development, Late Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA. ^[2] Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden. ^[3] Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, South San Francisco, CA, USA. ^[4] Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, USA. ^[5] Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, UK. ^[6]

主题词人类(Humans);抗体, 单克隆(Antibodies, Monoclonal);红斑狼疮, 系统性(Lupus Erythematosus, Systemic);治疗结果(Treatment Outcome)

DOI 10.1007/s40262-023-01238-2

PMID 37148484

发布时间 2024-09-18

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交